Charme Capital Partners agrees the sale of Igenomix to EQT
- Igenomix is one of the world’s leading biotechnology companies with a proprietary portfolio of products and therapies focused on women’s health and reproductive genetics
- Since 2016, Charme Capital Partners has successfully partnered with management actively supporting Igenomix’s international expansion by creating a global platform of labs in leading markets; further invested and developed its world-leading R&D function; and launched new and innovative proprietary products
- Charme is a strong believer in the industry and is currently working in order to recommit in a broader transaction also involving a minority stake in Igenomix that will be announced in the next weeks
Charme Capital Partners (“Charme”), the pan-European mid-market private equity firm, has announced today that Charme III, its €650m buyout fund, has reached an agreement to sell a majority stake in Igenomix to EQT, the global investment firm founded by the Wallenberg family in the 90’s with more than 50 billion of commitments raised since inception. Igenomix is the leading global provider of woman health and reproductive genetic services. As part of the transaction, Igenomix’s senior management will reinvest in the company, in order to continue to support its long-term growth and success.
Igenomix, headquartered in Valencia, Spain, uses the most advanced technology to offer pioneering genetic testing services in reproductive medicine. It works closely with IVF (In-Vitro-Fertilization) clinics around the world to help increase the chances of successful pregnancies and aid medical professionals in delivering healthier babies. Today, Igenomix helps patients across the globe from 15 advanced laboratories in 13 different countries and has multiple promising new patents currently undergoing pre-clinical studies.
Charme first invested in Igenomix in 2016 and since then it has actively worked together with the CEO David Jimenez and the R&D team composed of 25 top class scientists and researchers led by Professor Carlos Simon.
Charme, leveraging on its 15-year track record of transforming mid-market companies into global leaders, actively worked with the management to expand Igenomix internationally by strengthening its market position in the US and expanding into several new markets such as the UK, Japan, Canada, Argentina, Italy, Turkey, and Kuwait; and widening its product offering through the launch of innovative proprietary new genetic tests.
During its ownership period, Charme has heavily invested to support the management team’s continued development of Igenomix’s world-class R&D function and the formation of joint R&D efforts with leading universities, including Stanford, Harvard and Baylor.
This active ownership model, typical of the Charme Funds, led to a 54% compound annual growth rate of revenues since 2015, and to a 53% compound annual growth rate of EBITDA.
Matteo di Montezemolo, Founder and Managing Partner of Charme Capital Partners, commented:
“Igenomix growth story is in line with the long standing track record of the Charme Funds in supporting mid-market local companies in becoming global leaders in their respective markets and confirms, once again, the consistency of Charme’s operating model. I would like to personally thank, also on behalf of all Charme III investors, Professor Carlos Simon, David Jimenez and the full Igenomix team for their extraordinary results, that I am sure will further improve over the next years.”
Francisco Churtichaga, Partner at Charme Capital Partners, said:
“Igenomix has been an incredible growth story and it has been a pleasure to help the founders internationalise the business and take the company to the next level. When we first invested in Igenomix we were excited by the potential of such a high-growth, technology-driven business and we look forward to continuing to support EQT, the company and its talented management team.”
David Jimenez, Chief Executive Officer of Igenomix, said:
“Charme’s resources, industry experience and strategic vision have been a differentiating factor during the company’s period of high growth over the past few years. We would like to thank their team for all their help and we look forward that they will continue to back Igenomix’s continued development as we enter the next phase of our journey.”